SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 22.1% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 49,429,420 shares, a growth of 22.1% from the December 15th total of 40,466,622 shares. Based on an average daily volume of 11,457,774 shares, the days-to-cover ratio is currently 4.3 days. Approximately 35.1% of the company’s stock are short sold. Approximately 35.1% of the company’s stock are short sold. Based on an average daily volume of 11,457,774 shares, the days-to-cover ratio is currently 4.3 days.

SELLAS Life Sciences Group Stock Up 8.5%

SELLAS Life Sciences Group stock opened at $4.32 on Wednesday. SELLAS Life Sciences Group has a 52 week low of $0.85 and a 52 week high of $5.18. The company’s 50 day moving average price is $2.59 and its two-hundred day moving average price is $2.08. The stock has a market cap of $615.34 million, a P/E ratio of -15.43 and a beta of 2.26.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. On average, equities analysts anticipate that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

Insider Activity

In other SELLAS Life Sciences Group news, Director Katherine Bach Kalin purchased 63,400 shares of SELLAS Life Sciences Group stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average price of $1.59 per share, with a total value of $100,806.00. Following the transaction, the director owned 104,400 shares in the company, valued at $165,996. This trade represents a 154.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Axxcess Wealth Management LLC bought a new position in SELLAS Life Sciences Group during the third quarter valued at about $26,000. BNP Paribas Financial Markets boosted its stake in SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after acquiring an additional 9,299 shares during the last quarter. Blair William & Co. IL purchased a new position in SELLAS Life Sciences Group in the second quarter valued at about $35,000. ProShare Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at approximately $43,000. Finally, Sei Investments Co. purchased a new stake in shares of SELLAS Life Sciences Group during the 3rd quarter worth approximately $43,000. 17.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, SELLAS Life Sciences Group currently has an average rating of “Hold” and a consensus price target of $7.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.